These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 27795554)

  • 1. Monitoring therapy responses at the leukemic subclone level by ultra-deep amplicon resequencing in acute myeloid leukemia.
    Ojamies PN; Kontro M; Edgren H; Ellonen P; Lagström S; Almusa H; Miettinen T; Eldfors S; Tamborero D; Wennerberg K; Heckman C; Porkka K; Wolf M; Kallioniemi O
    Leukemia; 2017 May; 31(5):1048-1058. PubMed ID: 27795554
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Individualized systems medicine strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia.
    Pemovska T; Kontro M; Yadav B; Edgren H; Eldfors S; Szwajda A; Almusa H; Bespalov MM; Ellonen P; Elonen E; Gjertsen BT; Karjalainen R; Kulesskiy E; Lagström S; Lehto A; Lepistö M; Lundán T; Majumder MM; Marti JM; Mattila P; Murumägi A; Mustjoki S; Palva A; Parsons A; Pirttinen T; Rämet ME; Suvela M; Turunen L; Västrik I; Wolf M; Knowles J; Aittokallio T; Heckman CA; Porkka K; Kallioniemi O; Wennerberg K
    Cancer Discov; 2013 Dec; 3(12):1416-29. PubMed ID: 24056683
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genomic complexity and dynamics of clonal evolution in childhood acute myeloid leukemia studied with whole-exome sequencing.
    Masetti R; Castelli I; Astolfi A; Bertuccio SN; Indio V; Togni M; Belotti T; Serravalle S; Tarantino G; Zecca M; Pigazzi M; Basso G; Pession A; Locatelli F
    Oncotarget; 2016 Aug; 7(35):56746-56757. PubMed ID: 27462774
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of acute myeloid leukemia in the next decade - Towards real-time functional testing and personalized medicine.
    Lam SS; He AB; Leung AY
    Blood Rev; 2017 Nov; 31(6):418-425. PubMed ID: 28797519
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clonal heterogeneity as detected by metaphase karyotyping is an indicator of poor prognosis in acute myeloid leukemia.
    Bochtler T; Stölzel F; Heilig CE; Kunz C; Mohr B; Jauch A; Janssen JW; Kramer M; Benner A; Bornhäuser M; Ho AD; Ehninger G; Schaich M; Krämer A
    J Clin Oncol; 2013 Nov; 31(31):3898-905. PubMed ID: 24062393
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human AML-iPSCs Reacquire Leukemic Properties after Differentiation and Model Clonal Variation of Disease.
    Chao MP; Gentles AJ; Chatterjee S; Lan F; Reinisch A; Corces MR; Xavy S; Shen J; Haag D; Chanda S; Sinha R; Morganti RM; Nishimura T; Ameen M; Wu H; Wernig M; Wu JC; Majeti R
    Cell Stem Cell; 2017 Mar; 20(3):329-344.e7. PubMed ID: 28089908
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ultra-deep sequencing leads to earlier and more sensitive detection of the tyrosine kinase inhibitor resistance mutation T315I in chronic myeloid leukemia.
    Baer C; Kern W; Koch S; Nadarajah N; Schindela S; Meggendorfer M; Haferlach C; Haferlach T
    Haematologica; 2016 Jul; 101(7):830-8. PubMed ID: 27102501
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Personalized therapy for acute myeloid leukemia.
    Hourigan CS; Karp JE
    Cancer Discov; 2013 Dec; 3(12):1336-8. PubMed ID: 24327695
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantitative detection of DNMT3A R882H mutation in acute myeloid leukemia.
    Berenstein R; Blau IW; Suckert N; Baldus C; Pezzutto A; Dörken B; Blau O
    J Exp Clin Cancer Res; 2015 May; 34(1):55. PubMed ID: 25994761
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selective Inhibitors of Histone Deacetylases 1 and 2 Synergize with Azacitidine in Acute Myeloid Leukemia.
    Min C; Moore N; Shearstone JR; Quayle SN; Huang P; van Duzer JH; Jarpe MB; Jones SS; Yang M
    PLoS One; 2017; 12(1):e0169128. PubMed ID: 28060870
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current treatment of acute myeloid leukemia.
    Roboz GJ
    Curr Opin Oncol; 2012 Nov; 24(6):711-9. PubMed ID: 23014187
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecularly targeted therapy in acute myeloid leukemia.
    Gill H; Leung AY; Kwong YL
    Future Oncol; 2016 Mar; 12(6):827-38. PubMed ID: 26828965
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A chemogenomic approach to identify personalized therapy for patients with relapse or refractory acute myeloid leukemia: results of a prospective feasibility study.
    Collignon A; Hospital MA; Montersino C; Courtier F; Charbonnier A; Saillard C; D'Incan E; Mohty B; Guille A; Adelaïde J; Carbuccia N; Garnier S; Mozziconacci MJ; Zemmour C; Pakradouni J; Restouin A; Castellano R; Chaffanet M; Birnbaum D; Collette Y; Vey N
    Blood Cancer J; 2020 Jun; 10(6):64. PubMed ID: 32488055
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Whole-exome sequencing reveals the spectrum of gene mutations and the clonal evolution patterns in paediatric acute myeloid leukaemia.
    Shiba N; Yoshida K; Shiraishi Y; Okuno Y; Yamato G; Hara Y; Nagata Y; Chiba K; Tanaka H; Terui K; Kato M; Park MJ; Ohki K; Shimada A; Takita J; Tomizawa D; Kudo K; Arakawa H; Adachi S; Taga T; Tawa A; Ito E; Horibe K; Sanada M; Miyano S; Ogawa S; Hayashi Y
    Br J Haematol; 2016 Nov; 175(3):476-489. PubMed ID: 27470916
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Revealing very small FLT3 ITD mutated clones by ultra-deep sequencing analysis has important clinical implications in AML patients.
    Zuffa E; Franchini E; Papayannidis C; Baldazzi C; Simonetti G; Testoni N; Abbenante MC; Paolini S; Sartor C; Parisi S; Marconi G; Cattina F; Bochicchio MT; Venturi C; Ottaviani E; Cavo M; Martinelli G
    Oncotarget; 2015 Oct; 6(31):31284-94. PubMed ID: 26384303
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Functional heterogeneity of genetically defined subclones in acute myeloid leukemia.
    Klco JM; Spencer DH; Miller CA; Griffith M; Lamprecht TL; O'Laughlin M; Fronick C; Magrini V; Demeter RT; Fulton RS; Eades WC; Link DC; Graubert TA; Walter MJ; Mardis ER; Dipersio JF; Wilson RK; Ley TJ
    Cancer Cell; 2014 Mar; 25(3):379-92. PubMed ID: 24613412
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient-tailored analysis of minimal residual disease in acute myeloid leukemia using next-generation sequencing.
    Malmberg EB; Ståhlman S; Rehammar A; Samuelsson T; Alm SJ; Kristiansson E; Abrahamsson J; Garelius H; Pettersson L; Ehinger M; Palmqvist L; Fogelstrand L
    Eur J Haematol; 2017 Jan; 98(1):26-37. PubMed ID: 27197529
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Toward Individualized Therapy in Acute Myeloid Leukemia: A Contemporary Review.
    Kadia TM; Ravandi F; Cortes J; Kantarjian H
    JAMA Oncol; 2015 Sep; 1(6):820-8. PubMed ID: 26181162
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Precision medicine for acute myeloid leukemia.
    Lai C; Karp JE; Hourigan CS
    Expert Rev Hematol; 2016 Jan; 9(1):1-3. PubMed ID: 26514194
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Detection of heterogeneity and evolution of subclones in t(8;21) AML by QM-FISH].
    Wang YC; Hu LP; Lin D; Li CW; Yuan T; Jia YJ; Tian Z; Tang KJ; Wang M; Wang JX
    Zhonghua Xue Ye Xue Za Zhi; 2013 Oct; 34(10):844-50. PubMed ID: 24171957
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.